We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allos Therapeutics, Inc. (MM) | NASDAQ:ALTH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.83 | 0 | 01:00:00 |
Issuer Free Writing Prospectus
Filed pursuant to Rule 433
Registration Statement No. 333-160679
(Supplementing Preliminary Prospectus Supplement
dated October 5, 2009)
14,000,000 Shares
Allos Therapeutics, Inc.
Common Stock
This free writing prospectus relates only to the securities described below and should be read together with the preliminary prospectus supplement dated October 5, 2009 (including the base prospectus dated August 28, 2009 and the documents incorporated by reference therein) relating to these securities.
Terms and Conditions of the Common Stock Offering
Number of Shares of Common Stock |
|
14,000,000 |
|
|
|
Overallotment Option |
|
2,100,000 |
|
|
|
Public Offering Price per Share |
|
$7.10 |
|
|
|
Underwriting Discounts and Commissions per Share |
|
$0.40825 |
|
|
|
Proceeds |
|
Approximately $93.0 million, or approximately $107.1 million if the underwriters over-allotment option is exercised in full, after deducting the underwriting discounts and commissions and estimated offering expenses. |
|
|
|
Dilution |
|
Allos
net tangible book value at June 30, 2009 was approximately
$100.6 million, or $1.13 per share. After giving effect to the sale of
14,000,000 shares of common stock by Allos at the offering price of $7.10 per
share, less underwriting
discounts and commissions and estimated offering expenses payable by Allos,
Allos net tangible book value at June 30, 2009, would have been
approximately $193.6 million, or $1.87 per share. This represents an
immediate increase in the net tangible book value of $0.74 per share to
existing Allos stockholders and an immediate dilution of $5.23 per share to
investors in this offering.
|
|
|
|
Trade Date |
|
October 7, 2009 |
|
|
|
Settlement Date |
|
October 13, 2009 |
|
|
|
Underwriters |
|
J.P. Morgan Securities Inc., Citigroup Global Markets Inc., Leerink Swann LLC, JMP Securities LLC, Needham & Company, LLC and RBC Capital Markets. |
The issuer has filed a registration statement (including a prospectus and preliminary prospectus supplement thereto) with the Securities and Exchange Commission, or SEC, for the offering to which this communication relates. Before you invest, you should read the prospectus and preliminary prospectus supplement in that registration statement (including the documents incorporated by reference therein) and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SECs web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and preliminary prospectus supplement if you request it by calling J.P. Morgan Securities Inc. at (718) 242-8002 or Citigroup Global Markets Inc. at (800) 831-9146.
1 Year Allos Therapeutics, Inc. (MM) Chart |
1 Month Allos Therapeutics, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions